Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib + TCS in Moderate to Severe Atopic Dermatitis (BREEZE-AD7)
NCT03733301Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a >= 2 Point Improvement at Week 16. Started Nov 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03733301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733301.